Sign In
Last checked at 
18 Jun 2025 07:00
18 June 2025
Kromek Group plc
("Kromek" or the "Group")
Capital Markets Day
Kromek (AIM: KMK), a global detection company delivering best-in-class solutions for the advanced imaging and CBRN detection markets, is hosting a capital markets day (the "CMD") later today for analysts and institutional investors.
The event will provide an opportunity to gain a deeper understanding of the Group's growth strategy, meet members of the wider leadership team and hear from external industry representatives.
As part of the presentations outlining Kromek's plan to deliver sustainable growth, the event will cover:
· The strong foundations of the Kromek business today
· Advanced Imaging and CBRN Detection as the key platforms for growth
· The medium-term target to scale the business to achieve revenues in excess of £60m and a 30% EBITDA margin
Consistent with the Board's focus to further investors' understanding of the strategic value of Kromek's business, the Group confirms that it will be reporting revenue by division with effect from its upcoming results announcement for the financial year to 30 April 2025. At the CMD, management will be providing the following disclosure on revenue by division for the last three reported financial years:
FY 2022 | FY 2023 | FY 2024 | |
Advanced Imaging | £4.7m | £8.7m | £9.0m |
CBRN Detection | £7.3m | £8.6m | £10.4m |
Total Group | £12.1m | £17.3m | £19.4m |
No additional new material information is being disclosed and the Group is not providing an update on current trading. In the Group's post year-end trading update of 8 May 2025, Kromek stated that 'as a consequence of the positive financial impact of the partnership with Siemens Healthineers, Kromek expects to report FY 2025 revenue ahead of market expectations, of not less than £26 million, representing year-on-year growth of at least 34%.'
The presentation materials, including a recording, will be available in the Investor Relations section of Kromek's website after the event: https://www.kromek.com/investor-relations/.
The CMD will take place at the offices of Cavendish Capital Markets at One Bartholomew Close, London, EC1A 7BL. Registration is from 2.00pm with the presentations scheduled to run from 2.15pm to 4.20pm followed by Q&A.
Institutional investors and analysts wishing to attend the CMD should register their interest by emailing ir@cavendish.com.
Retail Investor Webinar
The Group is hosting an online Q&A session for retail investors at 5.00pm on Wednesday 25 June 2025 on the Investor Meet Company platform. Questions can be submitted pre-webinar via the Investor Meet Company platform up until 9.00am on 23 June 2025 or at any time during the live webinar. Investors can sign up to Investor Meet Company for free and register to attend the Kromek Q&A session via:
https://www.investormeetcompany.com/kromek-group-plc/register-investor.
Kromek Group plc | |
Arnab Basu, CEO Claire Burgess, CFO | +44 (0)1740 626 060 |
| |
Cavendish Capital Markets Limited (Nominated Adviser and Broker) |
|
Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance Tim Redfern - ECM Michael Johnson - Sales | +44 (0)20 7220 0500
|
Gracechurch Group (Financial PR) | |
Harry Chathli/Claire Norbury/Henry Gamble | +44 (0)20 4582 3500 |
Kromek Group plc
Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.
The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.
In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.
The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.
Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.
Follow the stocks
